GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-05 07:30 |
GENFIT to Present Latest ACLF Research at EASL Congress 2025
|
English | 220.7 KB | ||
| 2025-04-29 21:10 |
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du R…
|
French | 516.5 KB | ||
| 2025-04-29 21:10 |
GENFIT Announces Publication of the 2024 Universal Registration Document and th…
|
English | 648.6 KB | ||
| 2025-04-29 12:14 |
Document d'Enregistrement Universel 2024
|
French | 10.4 MB | ||
| 2025-04-28 22:10 |
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Chola…
|
French | 181.9 KB | ||
| 2025-04-28 22:10 |
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosi…
|
English | 189.9 KB | ||
| 2025-04-24 22:10 |
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
|
English | 282.4 KB | ||
| 2025-04-24 22:10 |
GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Soc…
|
French | 317.3 KB | ||
| 2025-03-10 22:10 |
Royalty Financing avec HCRx : GENFIT annonce l’approbation de la modification d…
|
French | 162.2 KB | ||
| 2025-03-10 22:10 |
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the …
|
English | 160.7 KB | ||
| 2025-02-27 22:10 |
GENFIT Announces Revenues and Cash Position as of December 31, 2024
|
English | 191.9 KB | ||
| 2025-02-27 22:10 |
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décemb…
|
French | 182.9 KB | ||
| 2025-02-14 22:10 |
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2…
|
English | 176.6 KB | ||
| 2025-02-14 22:10 |
GENFIT annonce la modification des termes définitifs de la double proposition a…
|
French | 213.3 KB | ||
| 2025-01-13 22:10 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commer…
|
English | 286.5 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
